Elabela
Elabela (ELA / Toddler)
An endogenous APJ receptor ligand discovered in 2013. Has cardioprotective, renal protective, and blood pressure-lowering properties. Deficiency is associated with preeclampsia.
Mechanism of Action
Elabela binds to APJ receptors with higher affinity than Apelin. It activates PI3K-Akt and ERK pathways, producing vasodilation, renal protection, and anti-fibrotic effects.
Health Claims & Evidence
Blood pressure reduction and cardiovascular protection
Renal protective effects
Potential preeclampsia treatment
Short-Term Effects
Vasodilation, renal protection.
Long-Term Effects
Research use primarily.
Side Effects
Very limited human data.
Contraindications
Limited human safety data.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
Elabela is an endogenous growth factor that sustains hESC self-renewal
Chng et al. · Cell Stem Cell · 2013
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on Elabela and related peptides, and prepare an educational research summary.
Explore Research